VTGN (Vistagen Therapeutics, Inc. Common Stock) Stock Analysis - Financials

Vistagen Therapeutics, Inc. Common Stock (VTGN) is a publicly traded Healthcare sector company. As of May 21, 2026, VTGN trades at $0.63 with a market cap of $23.59M and a P/E ratio of -0.38. VTGN moved +1.22% today. Year to date, VTGN is -11.14%; over the trailing twelve months it is -75.67%. Its 52-week range spans $0.43 to $5.14. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces VTGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are VTGN's key financials?

VTGN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VTGN recently traded at $0.63. Market cap is $23.59M. P/E ratio is -0.38. Revenue is $486.00K.

VTGN Key Metrics

Key financial metrics for VTGN
MetricValue
Price$0.63
Market Cap$23.59M
P/E Ratio-0.38
EPS$-1.67
Dividend Yield0.00%
52-Week High$5.14
52-Week Low$0.43
Volume822
Avg Volume0
Revenue (TTM)$486.00K
Net Income$-51.42M
Gross Margin0.00%

VTGN Annual Financials

YearRevenueNet IncomeEPS
2025$486.00K$-51.42M$-1.67
2024$1.06M$-29.36M$-1.52
2023$-227.00K$-59.25M$-8.51
2022$1.11M$-47.76M$-0.25

Latest VTGN News

VTGN Analyst Consensus

1 analysts cover VTGN: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.

Common questions about VTGN

What are VTGN's key financials?
VTGN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. VTGN recently traded at $0.63. Market cap is $23.59M. P/E ratio is -0.38. Revenue is $486.00K.
Is VTGN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VTGN. It does not provide personalized investment advice.
VTGN

VTGN